StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Adaptimmune Therapeutics's total assets was $130.63M at Jun 30, 2025. For fiscal 2024 it was $245.96M, down 13.0% from the year before. The highest annual figure on record is $469.55M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2024Dec 31, 2024$245.96M-13.0%
FY2023Dec 31, 2023$282.62M-14.1%
FY2022Dec 31, 2022$328.92M-30.0%
FY2021Dec 31, 2021$469.55M+4.1%
FY2020Dec 31, 2020$451.14M+148.5%
FY2019Dec 31, 2019$181.54M-34.4%
FY2018Dec 31, 2018$276.74M-1.6%
FY2017Dec 31, 2017$281.15M-6.5%
FY2015Jun 30, 2015$300.65M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2025CQ2 2025Jun 30, 2025$130.63M-59.4%
Q1 FY2025CQ1 2025Mar 31, 2025$158.07M-38.7%
Q4 FY2024CQ4 2024Dec 31, 2024$245.96M-13.0%
Q3 FY2024CQ3 2024Sep 30, 2024$317.44M+7.0%
Q2 FY2024CQ2 2024Jun 30, 2024$321.70M-6.2%
Q1 FY2024CQ1 2024Mar 31, 2024$258.01M-10.4%
Q4 FY2023CQ4 2023Dec 31, 2023$282.62M-14.1%
Q3 FY2023CQ3 2023Sep 30, 2023$296.64M-10.7%
Q2 FY2023CQ2 2023Jun 30, 2023$342.98M-11.7%
Q1 FY2023CQ1 2023Mar 31, 2023$288.08M-31.4%
Q4 FY2022CQ4 2022Dec 31, 2022$328.92M-30.0%
Q3 FY2022CQ3 2022Sep 30, 2022$332.20M-6.0%
Q2 FY2022CQ2 2022Jun 30, 2022$388.27M-0.4%
Q1 FY2022CQ1 2022Mar 31, 2022$419.80M+2.0%
Q4 FY2021CQ4 2021Dec 31, 2021$469.55M+4.1%
Q3 FY2021CQ3 2021Sep 30, 2021$353.53M-26.2%
Q2 FY2021CQ2 2021Jun 30, 2021$389.79M-23.9%
Q1 FY2021CQ1 2021Mar 31, 2021$411.58M+44.3%
Q4 FY2020CQ4 2020Dec 31, 2020$451.14M+148.5%
Q3 FY2020CQ3 2020Sep 30, 2020$479.02M+130.0%
Q2 FY2020CQ2 2020Jun 30, 2020$512.20M+113.8%
Q1 FY2020CQ1 2020Mar 31, 2020$285.24M+5.5%
Q4 FY2019CQ4 2019Dec 31, 2019$181.54M-34.4%
Q3 FY2019CQ3 2019Sep 30, 2019$208.25M-32.7%
Q2 FY2019CQ2 2019Jun 30, 2019$239.52M+13.4%
Q1 FY2019CQ1 2019Mar 31, 2019$270.44M+9.5%
Q4 FY2018CQ4 2018Dec 31, 2018$276.74M-1.6%
Q3 FY2018CQ3 2018Sep 30, 2018$309.63M+2.7%
Q2 FY2018CQ2 2018Jun 30, 2018$211.30M-25.7%
Q1 FY2018CQ1 2018Mar 31, 2018$247.07M-7.1%
Q4 FY2017CQ4 2017Dec 31, 2017$281.15M-6.5%
Q3 FY2017CQ3 2017Sep 30, 2017$301.38M–
Q2 FY2017CQ2 2017Jun 30, 2017$284.28M–
Q1 FY2017CQ1 2017Mar 31, 2017$265.98M–
Q4 FY2015CQ2 2015Jun 30, 2015$300.65M–

More Adaptimmune Therapeutics figures

See a number that looks wrong?